All ideas Top 10 Trending Top 100 Business Ideas Top Google Searches Free to start AI businesses Kids and teens Senior Care 🔒 Blind Spot Index

Start a New-Billing-Code Market-Unlock Advisory for AI Diagnostics

People search: “how to start a reimbursement code strategy consultancy” (300+ per month)

Advise AI diagnostic companies on securing and leveraging dedicated reimbursement codes as the market-unlock catalyst, using the CPT 92229 pattern that made AI eye screening commercially viable.

People look up how to start a reimbursement code strategy consultancy every single day, and most of what comes back is hype. Here is the honest breakdown instead: what this really is, what it costs, and how to begin.

✨ Customize this idea to me 📖 Read the full playbook ↓

Keep browsing: All ideas · Top 10 · AI businesses · Free to start · More Healthcare Reimbursement

Difficulty

Advanced

Startup cost

$2,000 to $30,000 (professional setup, research tools, marketing)

Time to first $

2 to 9 months

Revenue potential

High

Profit margin

55 to 80% net on consulting fees

Viability ⓘ

6.5 / 10

Search demand

Low (300+ per month on Google)

Where it runs

Online

Best for: Reimbursement strategists and health-policy experts advising AI diagnostic companies

The ideaWhat this actually is

This is a new-billing-code market-unlock advisory for AI diagnostics. The creation of a dedicated CPT code (92229) for AI-diagnostic retinal screening is the cleanest example of a regulatory catalyst turning a research curiosity into a commercially viable category, because a screen a buyer cannot bill for does not get adopted. Distinct from a generic device reimbursement consultancy, the specific angle is new-billing-code-as-market-catalyst strategy for AI diagnostics across any specialty.

The opportunityWhy this idea works

Most AI diagnostic founders obsess over the algorithm and FDA clearance and underestimate the billing-code question that actually decides adoption, so an advisor who specializes in new-billing-code strategy fills a real gap. Because a screen buyers cannot bill for does not get adopted, the reimbursement pathway is the market unlock. It is a low-startup, high-margin consultancy (55 to 80 percent net) with a specific, transferable angle.

The openingWhy this idea is overlooked

The creation of a dedicated CPT code (92229) for AI-diagnostic retinal screening is the cleanest example of a regulatory catalyst turning a research curiosity into a commercially viable category, because a screen a buyer cannot bill for does not get adopted. Most AI diagnostic founders obsess over the algorithm and FDA clearance and completely underestimate the billing-code question that decides adoption. The overlooked, specific angle is new-billing-code-as-market-catalyst strategy for AI diagnostics across any specialty.

The buildWhat you need to build this

You need	Why it matters
Reimbursement and CPT-code expertise	Understanding how new billing codes (like CPT 92229) unlock markets is the core knowledge of the service.
AI-diagnostics domain knowledge	Advising AI diagnostic founders requires understanding their products and adoption barriers.
A billing-code-as-catalyst methodology	The specific angle is new-billing-code-as-market-catalyst strategy, so a repeatable methodology is the intellectual property.
Cross-specialty applicability	The angle transfers to AI diagnostics across any specialty, widening the client base.
Research tools	Understanding reimbursement pathways requires research tools and current billing knowledge.
Low startup capital	Startup runs $2,000 to $30,000 for professional setup, research tools, and marketing.

How to start a reimbursement code strategy consultancy: the honest path

People searching for how to start a reimbursement code strategy consultancy deserve a straight answer. The steps below are that answer, with the hype stripped out.

The roadmap

How to start, step by step

1
Master the billing-code creation and coverage process
The core expertise is how new CPT codes are created, valued, and covered: the CPT editorial process, the difference between a code existing and payers actually reimbursing it, and how a code like 92229 for AI retinal screening moved a category from unreimbursed cost to billable revenue. You need to understand both the mechanics and the timeline, which is often multi-year. This depth is the entire value proposition. Study real code-creation cases in detail.
2
Package the new-code-as-catalyst pattern
The transferable insight is that a dedicated reimbursement code can be the single catalyst that unlocks commercial viability for an AI diagnostic category, and the same pattern applies whenever a new AI diagnostic technology needs a realistic path to adoption rather than remaining a research curiosity. Turn that pattern into a repeatable diagnostic: does this technology have a viable code path, and what is the strategy and timeline to get there. A clear framework is what makes the advisory sellable. Build the methodology deliberately.
3
Position distinct from generic reimbursement consulting
A generic device reimbursement and market-access consultancy already exists in the market; your niche is specifically the billing-code strategy for AI diagnostics as the market-unlock catalyst. Sharpen the positioning so buyers understand you solve the exact question that decides whether their AI ever gets adopted. The specificity is the differentiator. Do not blur into general consulting.
4
Sell to AI diagnostic companies at the right moment
The buyers are AI diagnostic companies, investors doing diligence, and health systems evaluating adoption, and the highest-value moment is early, when a company is deciding whether and how to pursue a code before sinking years into a product with no reimbursement path. Reach them through content, health-tech networks, and referrals. Timing the engagement early is where you add the most value. Build relationships in the AI diagnostic and investor community.
5
Deliver strategy, not promises
Your deliverable is a realistic assessment and strategy: the code landscape, the path and timeline to a code or coverage, the interim options, and the honest odds, never a guarantee that a code will be created or that revenue will follow. Reimbursement outcomes depend on bodies you do not control, and the advisory has to say so. Honest, well-reasoned strategy is what earns repeat engagements and referrals. Sell clarity, not certainty.

The traps

Common mistakes that kill this business

Mistake	What happens
Focusing only on FDA clearance	Founders underestimate billing codes. An advisor who ignores reimbursement misses the question that actually decides adoption.
Generic reimbursement advice	The specific angle is new-billing-code-as-market-catalyst. Generic device-reimbursement advice does not capture it.
Not staying current on codes	Billing codes and pathways change. Stale knowledge produces advice that no longer unlocks the market.
Limiting to one specialty	The angle transfers across specialties. Limiting to ophthalmology leaves a wider client base untapped.

The money

How this idea makes money

Reimbursement-strategy engagements

AI diagnostic founders pay for new-billing-code strategy that unlocks adoption.

Market-access consulting

Advising on the reimbursement pathway that makes a diagnostic commercially viable is core value.

Cross-specialty engagements

Applying the billing-code-as-catalyst angle to AI diagnostics in other specialties widens revenue.

Retainer advisory

Ongoing reimbursement strategy as a company builds its product is recurring revenue.

Prove it to yourself

Run the numbers on this idea

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

What to charge calculator →Break-even calculator →All 33+ calculators

The start

Your first 7 days

Day 1Study how CPT 92229 unlocked the AI retinal-screening market.

Day 2Understand why a screen buyers cannot bill for does not get adopted.

Day 3Assess your reimbursement and CPT-code expertise.

Day 4Develop a new-billing-code-as-catalyst methodology.

Day 5Identify AI diagnostic founders who underestimate reimbursement.

Day 6Consider the cross-specialty applicability of the angle.

Day 7Package and price the advisory as market-unlock strategy.

The fit

Who this is for, and who it is not for

Best for: Reimbursement strategists and health-policy experts advising AI diagnostic companies

Not for: This is not for someone without genuine reimbursement and billing-code expertise. The advice must be correct and current. If you have that expertise, it is a low-capital, high-margin, transferable consultancy; a generic device-reimbursement consultancy is the broader, separate model.

Your first move

Build deep expertise in the CPT-code creation and coverage process, package the new-billing-code-as-catalyst pattern into a repeatable advisory, and sell to AI diagnostic companies assessing their real path to adoption.

🔒 The rest of the playbook is free

The step-by-step roadmap, the traps that kill this business, how it makes money, and your first 7 days. A free account unlocks every playbook forever, plus saving ideas and the tools to build this one.

Unlock the full playbook free →

Already a member? Log in and this opens.

The shortcut

Where Unleash Your Ideas comes in

Unleash Your Ideas can help you turn your reimbursement expertise into a new-billing-code-as-catalyst advisory and target the AI diagnostic founders who underestimate the question that decides adoption.

Three ways to act on this idea

Do it yourself

Use the platform free to turn this idea into your own execution plan: niche, offer, money path, and first steps.

Unleash This Idea Free

Guided

Get our team's help shaping the strategy, the setup, and the launch path with you.

Get Help Setting It Up

Done for you

Apply to have the strategy and buildout done with you or for you, with vetted specialists managed by one team.

Done For You

Make it yours

Customize this idea to me

Create your free account, Start a New-Billing-Code Market-Unlock Advisory for AI Diagnostics gets stored as YOURS, and Kenny, your AI build partner, rewrites the proven Unleash an Idea path around your version of it. Every idea you bring after this gets the same treatment.

✨ Customize this idea to me →

Keep browsing

Related ideas

Start a Medical Device Reimbursement and Market Access Consultancy →

Advanced · $1,000 to $12,000 · Viability 6.8/10

Start an International Reimbursement Arbitrage Advisory (NICE and DiGA) →

Advanced · $2,000 to $50,000 for a specialist market-access practice · Viability 6.7/10

Start a Diagnostic-Accessibility Market-Access Advisory →

Advanced · $5,000 to $40,000 to launch as a boutique advisory · Viability 6.1/10

Start an ABA Payer-Mix Optimization Advisory →

Advanced · $2,000 to $20,000 for a specialized advisory practice · Viability 6.5/10

Start a Diagnostic-Deskilling-Through-AI Strategy Consultancy →

Advanced · $2,000 to $30,000 (professional setup, research, marketing) · Viability 6.3/10

Start a Pacific Trade Agreement and Market-Access Consultancy →

Advanced · $1,000 to $20,000 (registration, professional setup, research tools) · Viability 6.2/10

Questions

What people ask about this idea

Why does a billing code matter so much?

Because a screen a buyer cannot bill for does not get adopted. The creation of CPT 92229 turned AI retinal screening from a research curiosity into a commercially viable category. Reimbursement, not just clearance, decides adoption.

What is the specific angle?

New-billing-code-as-market-catalyst strategy for AI diagnostics across any specialty, distinct from generic device-reimbursement consulting. It focuses on how a dedicated code unlocks a whole category.

Why do founders miss it?

They obsess over the algorithm and FDA clearance and underestimate the billing-code question, so an advisor who specializes in it fills a real gap.

What is startup cost?

Low, roughly $2,000 to $30,000 for professional setup, research tools, and marketing, with 55 to 80 percent net on consulting fees. It is an expertise business.

← Browse all business ideas